Cargando…

Regression of brain metastases from breast cancer with eribulin: a case report

BACKGROUND: Eribulin is a recently approved new therapeutic option for patients with metastatic breast cancer. According to several reports, eribulin has limited ability to cross the blood brain barrier. Recently, capecitabine and eribulin have been recognized as drugs with similar application for p...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuoka, Hiromichi, Tsurutani, Junji, Tanizaki, Junko, Iwasa, Tsutomu, Komoike, Yoshifumi, Koyama, Atsuko, Nakagawa, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3878316/ https://www.ncbi.nlm.nih.gov/pubmed/24350786 http://dx.doi.org/10.1186/1756-0500-6-541

Ejemplares similares

Multicentre, phase II study of eribulin in combination with S-1 in patients with advanced breast cancer
por: Iwasa, Tsutomu, et al.
Publicado: (2019)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

Phase I study of weekly nab-paclitaxel combined with S-1 in patients with human epidermal growth factor receptor type 2-negative metastatic breast cancer
por: Tsurutani, Junji, et al.
Publicado: (2015)

A phase I dose-escalation study of eribulin and S-1 for metastatic breast cancer
por: Sakiyama, T, et al.
Publicado: (2015)

Lentinula edodes mycelia extract plus adjuvant chemotherapy for breast cancer patients: Results of a randomized study on host quality of life and immune function improvement
por: Nagashima, Yukiko, et al.
Publicado: (2017)

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study
por: Tsurutani, Junji, et al.
Publicado: (2018)

Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine
por: Matsuoka, Hiromichi, et al.
Publicado: (2017)

Indices of peripheral leukocytes predict longer overall survival in breast cancer patients on eribulin in Japan
por: Takahashi, Masato, et al.
Publicado: (2021)

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study)
por: Matsuoka, Hiromichi, et al.
Publicado: (2017)

Incidence of carnitine deficiency in patients with cancer pain: A pilot study
por: Sakai, Kiyohiro, et al.
Publicado: (2017)

Eribulin Efficacy on Brain Metastases in Heavily Pretreated Patients with Metastatic Breast Cancer
por: Sabatier, Renaud, et al.
Publicado: (2021)

Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain
por: Fujita, Yoshihiko, et al.
Publicado: (2023)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
por: Watanabe, Satomi, et al.
Publicado: (2019)

Brain Metastases from Breast Cancer and Response to Treatment with Eribulin: A Case Series
por: Chang, Alex Y, et al.
Publicado: (2015)

Effectiveness and safety of eribulin in Japanese patients with HER2-negative, advanced breast cancer: a 2-year post-marketing observational study in a real-world setting
por: Inoue, Kenichi, et al.
Publicado: (2020)

Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid
por: Yanae, Masashi, et al.
Publicado: (2017)

A Case of Brain Metastases from Breast Cancer Treated with Whole-Brain Radiotherapy and Eribulin Mesylate
por: Nieder, Carsten, et al.
Publicado: (2012)

Safety and effectiveness of eribulin in Japanese patients with locally advanced or metastatic breast cancer: a post-marketing observational study
por: Watanabe, Junichiro, et al.
Publicado: (2017)

Transient Effectiveness of an Oral 5-Fluorouracil Derivative, S-1, for Epirubicin, Cyclophosphamide and Paclitaxel Refractory Skin Metastases from Possible Occult Breast Cancer in a Male
por: Hirao, Ayaka, et al.
Publicado: (2011)

Preferences for oral versus intravenous adjuvant chemotherapy among early breast cancer patients
por: Ishitobi, Makoto, et al.
Publicado: (2013)

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
por: Watanabe, Satomi, et al.
Publicado: (2018)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

Malignant Adenomyoepithelioma of the Breast and Responsiveness to Eribulin
por: Lee, Suee, et al.
Publicado: (2015)

Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)
por: Matsuoka, Hiromichi, et al.
Publicado: (2022)

Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors
por: Shimizu, Toshio, et al.
Publicado: (2016)

Inhibitory effects of iron depletion plus eribulin on the breast cancer microenvironment
por: Goto, Wataru, et al.
Publicado: (2020)

Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Eribulin mesylate in the treatment of metastatic breast cancer
por: Jain, Sarika, et al.
Publicado: (2012)

Correction to: Trastuzumab, pertuzumab, and eribulin mesylate versus trastuzumab, pertuzumab, and a taxane as a first-line or second-line treatment for HER2-positive, locally advanced or metastatic breast cancer: study protocol for a randomized controlled, non-inferiority, phase III trial in Japan (JBCRG-M06/EMERALD)
por: Yamashita, Toshinari, et al.
Publicado: (2020)

Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis
por: O’Shaughnessy, Joyce, et al.
Publicado: (2020)

Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
por: Kazmi, Shayma, et al.
Publicado: (2020)

Surgical therapy for pulmonary metastasis of breast cancer
por: Soh, Junichi, et al.
Publicado: (2020)

A randomized trial of eribulin monotherapy versus eribulin plus anlotinib in patients with locally recurrent or metastatic breast cancer
por: Liu, B., et al.
Publicado: (2023)

Correction to: Overall survival analysis in patients with metastatic breast cancer and liver or lung metastases treated with eribulin, gemcitabine, or capecitabine
por: Kazmi, Shayma, et al.
Publicado: (2021)

Eribulin for Advanced Breast Cancer: A Drug Evaluation
por: Shablak, Alaaeldin
Publicado: (2013)

Case Studies in the Management of Metastatic Breast Cancer with Eribulin
por: Wilks, Sharon, et al.
Publicado: (2015)

Eribulin drug review
por: Shetty, Nishitha, et al.
Publicado: (2014)

Eribulin in Cancer Treatment
por: Swami, Umang, et al.
Publicado: (2015)

Eribulin Mesylate Combined with Local Treatment for Brain Metastasis from Breast Cancer: Two Case Reports
por: Byun, Kyung-Do, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_s884b3mk48o8o6jtsn0b4voit6